null

null

null

null

null

null

null

null

null

null

null

null

null

null

Progyny carries minimal debt; net cash position ~$200M+, so a 20bps rate rise has negligible interest expense impact.

Low sensitivity; company is essentially debt-free with cash reserves, so rising rates modestly boost interest income rather than expense.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Not applicable in traditional sense; primary dependencies are fertility clinic network availability and specialty pharmacy (Alto/Progyny Rx) distribution.

Progyny operates almost exclusively in the U.S.; sovereign currency devaluation risk in international markets is effectively zero currently.

Overwhelmingly U.S.-only; no material international revenue, so currency devaluation exposure across foreign markets is negligible or null.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Progyny Rx specialty pharmacy is a significant captive revenue stream; fertility clinic network concentration in key metro areas poses substitutability risk.

Cloud disruption would impair member portal and data analytics but core benefit-administration operations could partially migrate; 30-day risk is moderate.

B2B2C fertility benefits manager; secondary model is pharmacy benefit through Progyny Rx, capturing ~40% of revenue from drug dispensing.

Moderate API coupling risk; integrated with large employer HR/benefits platforms (Workday, SAP) creating stickiness but not irreplaceable lock-in.

Fails Howey Test; revenue is a service-fee model (employer benefits contract), not an investment contract—Howey risk is essentially zero.

Very High

High HIPAA exposure given fertility/reproductive health data sensitivity; CCPA applies to California members; GDPR immaterial given no EU operations.

Low-to-moderate; could face scrutiny if clinic network exclusivity arrangements limit patient choice, but market share remains sub-5% of employer benefits.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~85-90% recurring via multi-year employer contracts; ~10-15% transactional through pharmacy dispensing volume tied to treatment cycles.

Per-member-per-month PMPM fee from employers plus per-treatment smart cycle fee and Progyny Rx pharmacy margin.

Smart cycle bundled pricing is differentiated but vulnerable to cost pressure from self-insured employers in a recessionary benefits-cutting environment.

Moderate-to-high; clinical outcomes data justifies premium pricing, but large employer procurement leverage caps annual price increases at ~3-5%.

23.6% Gross Margin (Moderate (20-40%))

Minimal free-rider leakage; employer pays regardless of member utilization, so unused benefit capacity does not erode unit economics materially.

Revenue growth is sublinear to headcount; clinical care advocates scale modestly with member volume but technology platform enables significant operating leverage.

Marginal cost of adding new employer clients is low; incremental pharmacy and care-advocate costs scale at roughly 40-50% of revenue growth rate.

Not a franchise model; not applicable.

At 10x scale, CAC efficiency improves as enterprise sales cycles amortize over larger contract base; benefit consultant channel reduces direct sales cost.

Weak direct network effects; larger member base strengthens clinic negotiating leverage and outcomes data, but members don't benefit from other members joining.

12.9% Return on Assets (Excellent)

Moderate vulnerability; fertility benefits are elective and among first cut by employers reducing benefits spend in a severe downturn.

Large self-insured employers (Fortune 500 and mid-market); top 10 clients likely represent 25-35% of revenue, indicating meaningful concentration risk.

Secondary segment is employees/members accessing fertility benefits; retention depends on employer renewal, not direct member relationships.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

1.4% CapEx / Revenue (Low-CapEx Asset-Light)

0001551306

PGNY